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a  b  s  t  r  a  c  t
Oral  lichen  planus  (OLP)  is  one  of the  most  common  diseases  of the  oral  mucosa.  Clinically,  it  has  speciﬁc
and  clearly  identiﬁable  features;  bilateral  symmetric  presentation  showing  a lace-like  network  of  ﬁne
white  lines  (known  as  Wickham’s  striae)  is  an  essential  element  of  OLP  even  if  the  lesion  exhibits  a  mainly
atrophic  and  erosive  pattern.  There  are  various  lesions  that  resemble  OLP  clinically  and  histologically.
These  lesions  are  widely  referred  to as lichenoid  reactions  or lichenoid  lesions  (OLLs).  OLLs  include  contact
hypersensitivity  to dental  materials,  drug-induced  lichenoid  lesions,  lichenoid  reactions  in chronic  graft-
versus-host  disease,  and  other  lesions  that  resemble  OLP.  The  risk of  malignant  transformation  of  OLP  is
the  subject  of ongoing  debate  in the  literature.  Some  authors  have  suggested  that  only  OLLs,  but  not  OLP,ifferential  diagnosis
ichenoid  dysplasia
alignant transformation
are  of  a premalignant  nature  and thus,  should  be categorized  as  “other  dysplastic  conditions.”  Contrary
to  this  suggestion,  many  cases  of  oral  squamous  cell  carcinoma  (OSCC)  developing  in  patients  with  OLP
presenting  with  no  epithelial  dysplasia  have  been  reported.  In  addition,  it has  been reported  that  multiple
events  including  multifocal  dysplasia  and/or  OSCC  subsequently  occurred  in some  patients  with  OLP,
suggesting  possible  ﬁeld  cancerization  in OLP. In  this  paper,  differential  diagnosis  between  OLP  and  OLLs
and  their  malignant  potential  are  reviewed.© 2013 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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. Introduction
Various white-and-red lesions occur in the oral mucosa, includ-
while the malignant potential of oral lichen planus (OLP) and/or oral
lichenoid lesions (OLLs) has been the subject of much discussion
in the past few decades [3–45]. Since the clinical and histologi-ng leukoplakia, erythroplakia, candidiasis, geographic tongue,
ichen planus, lichenoid lesions, and others. Oral leukoplakia and
ral erythroplakia are well known to be precancerous lesions [1,2],
∗ Correspondence to: A-901, 4-8 Kamishinden, Toyonaka-shi, Osaka 560-0085,
apan.  Tel.: +81 6 6832 5518.
E-mail  addresses: kshira@opal.ocn.ne.jp, shirasuna.kanemitsu@gmail.com
348-8643/$ – see front matter ©  2013 Japanese Stomatological Society. Published by Els
ttp://dx.doi.org/10.1016/S1348-8643(13)00030-Xcal features of these white-and-red lesions are similar, differential
diagnosis of them is important.
Lichen  planus is a chronic inﬂammatory mucocutaneous dis-
ease associated with immune-mediated pathogenesis [3–6]. It most
commonly affects the oral mucosa, but can involve other sites such
as the skin, genital mucosa, scalp, and nails [4–8]. Most cases of
OLP do not involve lesions at other sites. The prevalence rates of
OLP vary from 0.5% to 2.6% of the world population [3–6].
evier Ltd. All rights reserved.
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the essential clinical feature of OLP is deﬁned to be the presenceK.  Shirasuna / Oral Scienc
The mean age of OLP onset is the ﬁfth decade of life, and there
s a gender predilection with a female/male ratio of 2 to 3:1 [4–45].
he clinical presentation is almost always in a bilateral, symmetric
attern. The lesions are almost always seen at the buccal mucosa,
nd other sites including the gingiva, tongue, and lip mucosa may
lso be affected. Clinical features of OLP range from asymptomatic
eticular white lesions in atrophic mucosa, to erosive-ulcerative
reas accompanied by pain and discomfort, while the most charac-
eristic feature is the presence of a lace-like network of ﬁne white
ines.
One of the most important issues concerning OLP is the question
f its potential for malignant transformation into oral squamous
ell carcinoma (OSCC). This controversial issue includes diagnos-
ic criteria of OLP that require further discussion. In this paper,
ifferential diagnosis and malignant transformation of OLP are
eviewed.
. Etiopathogenesis
.1. Cell-mediated immunity
Although  the exact etiology of OLP remains uncertain, cumula-
ive evidence suggests that cell-mediated immunity plays a major
ole in the pathogenesis of OLP [3,7,46–56]. An immunological pro-
ess is believed to be triggered by an antigen that alters the basal
eratinocytes of the oral mucosa. Keratinocyte antigen expression
s induced by systemic drugs, contact allergen in dental restora-
ive materials, mechanical trauma, bacterial or viral infection, or
nidentiﬁed agents. Cytotoxic CD8+ T lymphocytes induce ker-
tinocyte apoptosis through immunoreactions triggered by one or
ore antigens associated with major histocompatibility complex
MHC) class I on basal keratinocytes [46–49]. The activated CD8+ T
ells secrete tumor necrosis factor (TNF)-alpha, which binds to the
NF-alpha receptor on keratinocytes, and then keratinocyte apo-
tosis occurs via the caspase cascade pathways [49–52]. Helper
D4+ T lymphocytes, which are activated by MHC  class II associated
ith Langerhans cells and keratinocytes, promote the cytotoxicity
f CD8+ T lymphocytes through various cytokines including inter-
eukin (IL)-2, IL-12, and interferon gamma  [3,47,53].
Mast cells and antigen-presenting Langerhans cells are also
nvolved in the local response. Activated chymase released by
egranulation of mast cells acts as a matrix metalloproteinase
hich degrades the extracellular matrix of basement membrane
nd contributes to the migration of lymphocytes to the connective
issues underneath the epithelial layer in OLP [54–56].
.2. Association with hepatitis C virus
Some reports have suggested a possible association between
LP and viral infections, such as herpes simplex virus, Epstein–Barr
irus, human papilloma virus [59,60], and hepatitis C virus (HCV)
61–77]. The most extensively studied virus is HCV, but its asso-
iation with OLP remains controversial. High prevalence rates of
CV infection in patients with OLP have been demonstrated in cer-
ain populations, mainly in the Mediterranean [61–63] and Asia
64–66], while this association between OLP and HCV is not found
n other areas, such as Northern Europe [67–70], suggesting geo-
raphic heterogeneity [71]. One explanation for the geographic
ifferences may  be genetic predisposition. For example, a higher
requency of the class II MHC  allele, DR6, has been reported in
talian OLP patients with HCV compared with those without HCV
72,73]. Contrary to expectations, a low incidence of OLP in an area
f southern Italy where HCV infection is hyperendemic has been
lso reported [74].rnational 11 (2014) 1– 7
A pathogenic role of HCV infection in OLP is still uncertain.
Detection of HCV RNA in the mucosal lesions of patients with OLP
[75,76], and the presence of HCV-speciﬁc CD4+ and CD8+ T lym-
phocytes in OLP lesions [77] suggest that epithelial cells expressing
HCV antigens may  be targets for the immunopathogenesis of OLP.
Another relevant issue is that OLP can be induced and/or aggravated
by antiviral treatment with either interferon-alpha or interferon-
alpha/ribavirin for HCV infection [78]. Additional reports indicate
an association between OLP and liver diseases in the absence of
HCV infection [79].
Further  investigations taking into account factors including HCV
genotype, race, area, age, gender, treatment (before or after), and
accessory co-infections such as candidiasis, are required to clarify
the role of HCV in OLP pathogenesis.
3. Clinical features
Clinically, OLP has speciﬁc and clearly identiﬁable features
[3–10]. OLPs are a mixture of white and red lesions that usually
exhibit multiple foci and almost always a bilateral symmetric pat-
tern. The most common site affected is the buccal mucosa, and some
cases involve other oral mucosal sites such as the tongue, gingivae,
and lower lip (in decreasing order of frequency). Lesions on palate,
oral ﬂoor, and upper lip are not common.
White lesions have a reticular, papule, plaque-like appear-
ance, and red lesions can appear atrophic (erythematous), erosive
(ulcerated), or bullous-like. OLP can be divided into the afore-
mentioned six types (reticular, papule, plaque, atrophic, erosive,
and bullous types), or two types, white and red, while it is most
commonly classiﬁed into three types, reticular, atrophic, and ero-
sive (Fig. 1A–C). Lesions are not homogenous and some cases may
present as a mixture of these clinical subtypes. White lesions gen-
erally form on a diffuse erythematous background. Reticular form,
which is the most common type and a characteristic feature of
OLP, shows a lace-like network of ﬁne white lines (known as Wick-
ham’s striae). Plaque forms appear as homogenous white patches
resembling leukoplakia. This form is often observed in the dorsum
of the tongue and the buccal mucosa. The presence of striation
in plaque forms may  help to distinguish them from leukoplakia.
The papular form consists of pinpoint white lesions, and is rarely
seen.
The erosive form is the next most common type, and is also a
signiﬁcant one for OLP. This form presents as atrophic and erythe-
matous areas with partial ulceration, which are often surrounded
by ﬁne white lines. When erosion is severe, the epithelium rup-
tures as in the case of benign mucous membrane pemphigoid. This
type, known as bullous form, is very rare. Atrophic form appears
as a diffuse red lesion with mucosal atrophy. Symptoms of burn-
ing or painful etching sensation are commonly associated with red
lesions including atrophic (erythematous) and erosive (ulcerated)
types.
If erosive forms of OLP are conﬁned to the gingival mucosa,
the condition is usually referred to as desquamative gingivitis
[45,46,57,58]. Such cases should be biopsied to distinguish them
from benign mucous membrane pemphigoid, pemphigus vulgaris,
and other malignancies.
The  World Health Organization (WHO) devised a set of diagnos-
tic criteria for OLP in 1978 (Table 1) [2] that was  revised in 2003
(Table 2) [10]. The modiﬁed WHO  diagnostic criteria involve differ-
entiation between OLP and OLLs. In these modiﬁed WHO  criteria,of bilateral lesions that exhibit a lace-like network of white lines
(reticular pattern), but not of plaque, atrophic, erosive, and bul-
lous lesions. When the bilateral reticular lesion is absent, then, it is
designated as “clinically compatible with OLP”.
K. Shirasuna / Oral Science International 11 (2014) 1– 7 3
F lar pattern showing a lace-like network of ﬁne white lines. White patches are partly seen.
( ticular lesions are formed on diffuse erythematous background. (D) Oral lichenoid lesion
s l mucosa adjacent to bridge, suggestive of contact allergy to dental materials.
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Table 2
Modiﬁed World Health Organization diagnostic criteria of OLP  and OLL (2003).
Clinical criteria
Presence of bilateral, more or less symmetrical lesions
Presence of a lace-like network of slightly raised gray-white lines (reticular
pattern)
Erosive, atrophic, bullous, and plaque-type lesions are accepted only as a
subtype in the presence of reticular lesions elsewhere in the oral mucosa
In all other lesions that resemble OLP but do not complete the aforementioned
criteria, the term “clinically compatible with” should be usedig. 1. Clinical appearance of oral lichen planus and oral lichenoid lesion. (A) Reticu
B)  Erosive pattern showing erythematous area with partial ulceration. (C) White re
howing  ulcerations surrounded by ﬁne white lines is solitary and located at bucca
. Histopathologic features
The  histopathology of OLP was ﬁrst described by Dubreuill in
906, and in 1972, it was revised by Shklar [11] who described
hree characteristic features: (1) overlying keratinization; (2) liq-
efaction degeneration of the basal cell layer; and (3) a dense
ubepithelial band of lymphocytes (Fig. 2). The 1978 WHO  diag-
ostic criteria [2] supported three ﬁndings as follows. (1) Usually
he keratinized layers exhibit either hyperparakeratosis or hyper-
rthokeratosis, often with a thickening of the granular cell layer
nd a saw-toothed appearance of the rete pegs. The saw-toothed
ppearance is common in the skin lesions, but less frequent in the
ral lesions. The thickness of the epithelium varies, but atrophy is
able 1
orld Health Organization diagnostic criteria of oral lichen planus (1978).
Clinical criteria
Presence of white papule, reticular, annular, plaque-type lesions, gray-white
lines radiating from the papules
Presence of a lace-like network of slightly raised gray-white lines (reticular
pattern)
Presence of atrophic lesions with or without erosion, may  also be bullae
Histopathologic criteria
Presence  of thickened ortho- or para-keratinized layer in sites normally
keratinized,  and if site normally nonkeratinized this layer may  be very thin
Presence of Civatte bodies in basal layer, epithelium, and superﬁcial part of the
connective tissue
Presence  of a well-deﬁned band-like zone of cellular inﬁltration that is
conﬁned to the superﬁcial part of the connective tissue, consisting mainly of
lymphocytes
Signs of ‘liquefaction degeneration’ in the basal cell layer
ata from Kramer et al. [2] with permission.
Histopathologic criteria
Presence  of a well-deﬁned band-like zone of cellular inﬁltration that is
conﬁned to the superﬁcial part of the connective tissue, consisting mainly of
lymphocytes
Signs of liquefaction degeneration in the basal cell layer
Absence  of epithelial dysplasia
When  the histopathologic features are less obvious, the term
“histopathologically compatible with” should be used
Final  diagnosis OLP or OLL
To achieve a ﬁnal diagnosis, clinical as well as histopathologic criteria should
be included
OLP: A diagnosis of OLP requires fulﬁllment of both clinical and
histopathologic  criteria
OLL:  The term OLL will be used under the following conditions:
1.  Clinically typical of OLP but histopathologically only compatible with
OLP
2. Histopathologically typical of OLP but clinically only compatible with
OLP
3. Clinically compatible with OLP and histopathologically compatible with
OLP
Data from van der Meiji et al. [10] with permission.
OLP, oral lichen planus; OLLs, oral lichenoid lesions.
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F en planus: e.g. hyperkeratosis with a saw-toothed rete pegs, liquefaction degeneration
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Table 3
Classiﬁcation of oral lichenoid lesions.
(1) Dental material
associated OLLs
Dental  amalgam
Resin-based materials
Metals
(2)  Drug-induced OLLs
NSAIDs
Antihypertensive agents (e.g. ACE
inhibitors)
Dapsone
Diuretics
Oral hypoglycemic agents
Gold  salts
Penicillamine
(3) Chronic graft-versus-host
disease
(4)  Unclassiﬁed OLLs
NSAIDs, non-steroidal anti-inﬂammatory drugs; ACE, angiotensin-convertingig. 2. Histology of oral lichen planus. Lesion shows typical histology of oral lich
arrow) of the basal cell layer, and a dense subepithelial band of lymphocytes (Ly).
ften seen and erosive epithelium is evident in some cases. (2) Liq-
efaction degeneration of the basal cell layer may  often be replaced
y an eosinophilic band. (3) A dense, band-like lymphocyte inﬁl-
ration in the superﬁcial part of the lamina propria and close to
he epithelium is composed largely of T cells. The presence of B
ells is uncommon. Another key feature of OLP is the presence of
ivatte (colloid) bodies containing one or more pyknotic nuclear
ragments in shrunken epithelial cells in the region of the basal cell
ayer.
These aspects of OLP are similar to OLLs. The WHO  criteria
or histopathologic diagnosis of OLP in 1978 did not describe the
ifference between OLP and OLLs. Eisenberg [9] has proposed a
et of essential and exclusionary histopathologic features of OLP.
he essential criteria are (a) basal cell liquefaction, (b) band-
ike lymphocytic inﬁltrate at the epithelial-stromal junction, with
bfuscation of the basal cell region, and (c) a normal epithe-
ial maturation pattern. Atypical cytomorphologies (suggestive of
pithelial dysplasia) including nucleus enlargement or hyperchro-
asia, prevalent dyskeratosis, and increased mitotic ﬁgures, are
xcluded from OLP diagnostic features. Heterogeneous popula-
ion of inﬂammatory inﬁltrate, deeper submucosal extension of
nﬁltrate beyond superﬁcial stroma, and perivascular inﬁltration
ndicate lichenoid inﬁltrate, rather than OLP.
A deﬁnitive diagnosis of OLP cannot be made on histopathologic
ndings only, but also requires clinical ﬁndings, and thus the mod-
ﬁed WHO  diagnostic criteria for OLP in 2003 proposes fulﬁllment
f both clinical and histopathologic criteria (Table 2) [10].
.  OLP and OLLs
Various  lesions resemble OLP clinically and histologically, and
hese are widely referred to as OLLs. OLLs can be classiﬁed into
our types; (1) contact hypersensitivity to dental materials, such
s amalgam restorations, (2) drug-induced lichenoid lesions, (3)
ichenoid reactions in chronic graft-versus-host disease (GVHD),
nd (4) other lesions that are unclassiﬁed (Table 3) [4,80].
.1.  Dental material-induced lichenoid lesions
Various kinds of dental materials, such as amalgam, metals,
omposite and resin-based materials are topographically associ-
ted with lichenoid reactions in oral mucosa (Fig. 1D) [4]. In most
ases these contact allergies are due to a type IV/delayed hyper-
ensitivity reaction. A patch test using the suspected materials is
elpful for diagnosis.enzyme; OLLs, oral lichenoid lesions.
5.2. Drug-induced lichenoid lesions
Certain medications, such as beta blockers, non-steroidal
anti-inﬂammatory drugs (NSAIDs), antihypertensive agents (e.g.
angiotensin-converting enzyme inhibitors), dapsone, diuretics, oral
hypoglycemic agents, gold salts, and penicillamine have been
reported to induce oral lichenoid reactions [4,81,82]. In some cases,
it may  be difﬁcult to distinguish drug-related OLLs from OLP,
clinically. Drug-related OLLs often involve the lip and exhibit a
symmetric distribution. Skin eruption may  suggest a drug-related
lesion. Drug-related OLLs may  resolve rapidly when the offending
drug is eliminated.
5.3.  Oral lichenoid reactions in chronic GVHD
Oral lichenoid reactions in chronic GVHD that occur after allo-
geneic bone marrow transplantation are well recognized [83–85].
Chronic GVHD is associated with lichenoid reactions that affect
both the skin, and mucus membranes. Intraoral lichenoid lesions
are similar to OLP, but tend to affect entire areas such as the buccal
mucosa, tongue, lips, and gingivae. Patients complain of a burning
sensation of the oral mucosa. Chronic GVHD often involves salivary
and lacrimal glands, and thus xerostomia is a common complaint.
In some cases, pyogenic granuloma is seen on the tongue.
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Table 4
Studies on the possible malignant transformation of oral lichen planus (1970–2013).
Authors Year Country No. of cases No. of MT  cases (%) Mean follow-up (years)
Shklar [11] 1972 USA 600 3 (0.5%)
Fulling [12] 1973 Denmark 225 1 (0.4%) 3.6
Kovesi  and Banoczy [13] 1973 Hungary 274 1 (0.4%)
Silverman et al. [14] 1985 USA 570 7 (1.2%) 5.6
Murti  et al. [15] 1986 India 702 3 (0.4%) 5.1
Holmstrup  et al. [16] 1988 Denmark 611 9 (1.5%) 7.5
Salem  [17] 1989 Saudi Arabia 72 4 (5.6%) 3.2
Silverman  et al. [18] 1991 USA 214 5 (2.3%) 7.5
Sigurgeirsson and Lindelöf [19] 1991  Sweden 2071 8 (0.4%) 9.9
Voûte et al. [20] 1992 The Netherlands 113 3 (2.7%) 7.8
Barnard  et al. [21] 1993 UK 241 8 (3.3%)
Moncarz et al. [22] 1993 Israel 280 6 (2.1%) 1.5
Gorsky  et al. [23] 1996 Israel 157 2 (1.3%) 4.8
Markopoulos et al. [24] 1997 Greece 326 4 (1.3%) 6.1
Silverman  and Bahl [25] 1997 USA 95 3 (3.2%) 5.7
Lo  Muzio et al. [26] 1998 Italy 263 13 (4.9%) 11.0
Rajentheran et al. [27] 1999 UK 832 7 (0.8%) 6.0
Mignogna  et al. [28] 2001 Italy 502 18 (3.7%)
Chainani-Wu et al. [29] 2001 USA 229 4 (1.7%) 4.5
Eisen  [30] 2002 USA 723 6 (0.8%)
Lanfranchi et al. [31] 2003 Argentina 719 32 (4.5%) 4.9
Gandolfo  et al. [32] 2004 Italy 402 9 (2.2%) HCV infected 6.8
Rödström  et al. [33] 2004 Sweden 1028 5 (0.5%)
Xue et al. [34] 2005 China 674 4 (0.6%) 4.3
Laeijendecker et al. [35] 2005  The Netherlands 200 3 (1.5%)
Bornstein et al. [36] 2006 Switzerland 145 1 [OLP] 4.8
3  [OLL]
Ingafou et al. [37] 2006 UK 690 13 (1.9%) 8.5
van  der Meij et al. [38] 2007 The Netherlands 67 [OLP] 0 (0%) [OLP]
192  [OLL] 4 (2.0%) [OLL] 10.2
Carbone  et al. [39] 2009 Italy 808 15 (1.85%)
Pakfetrat et al. [40] 2009 Iran 420 3 [OLL?] mild dysplasia
Bermejo-Fenoll et al. [41] 2010 Spain 550 8 (0.9%)
Bombeccari et al. [42] 2011 Italy 327 8 (2.4%)
Shen et al. [43] 2012 China 518 5 (0.96%)
Tovaru et al. [44] 2013 Romania 633 6 (0.95%)
Gumru et al. [45] 2013 Turkey 370 1 (0.27%) developed 2y later
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T,  malignant transformation; HCV, hepatitis C virus; OLP, oral lichen planus; OLL,
.4. Unclassiﬁed OLLs
There  are other lesions that have OLP-like features but can-
ot be classiﬁed via the aforementioned three types of OLLs. Waal
80] described lesions that had lichen planus-like characteristics
ut lacked one or more of the typical features, such as bilateral
resentation. These unclassiﬁed OLLs include those with erythe-
atous changes limited to the gingiva, without signs of “true”
LP elsewhere in the oral cavity. Such lesions may be identical to
esquamative gingivitis [46–49].
Eisenberg [9] has discussed other OLLs, such as nonspeciﬁc
ichenoid stomatitis, atypical lichenoid stomatitis, and lichenoid
ysplasia. The term “lichenoid dysplasia” was coined by Krutchkoff
nd Eisenberg [86] to describe lesions that resemble OLP clinically
nd histologically, but also show epithelial dysplasia. Eisenberg [9]
ater suggested that this term should be avoided, as it creates con-
usion, and dysplastic OLP is best allocated to the category “other
ysplastic conditions”.
.  Malignant transformation of OLP
One of the most important issues concerning OLP is its poten-
ial for malignant transformation into OSCC. Although the WHO
as categorized OLP as a precancerous condition [2], the risk of
alignant transformation of OLP remains a subject of debate in
he literature. Some authors accept the possible malignant poten-
ial of OLP, while others oppose this suggestion. Krutchkoff et al.
87] reviewed reports published from 1950 to 1978 evaluating thechenoid lesion.
premalignant potential of OLP, but did not ﬁnd sufﬁcient docu-
mented evidence to conﬁdently support the contention that OLP
represents a premalignant condition. A major problem in this
regard was  the lack of universally accepted speciﬁc diagnostic cri-
teria for OLP. Critics have pointed out that some cases of OLP that
progressed to OSCC were misdiagnosed as OLP from the beginning,
and that lichenoid lesions presenting dysplasia via biopsy should
be excluded from the diagnosis of OLP. Due to a lack of sufﬁcient
data to support the initial diagnosis of OLP in patients who ulti-
mately developed OSCC, modiﬁcations have been proposed to the
WHO  criteria published in 2003 [10]. Five-year follow-up of 192
patients with OLLs and 67 patients with OLP, selected using the
modiﬁed WHO  criteria, demonstrated development of OSCC in 4
cases of OLLs, and no cases of OLP, suggesting malignant poten-
tial of OLLs, but not OLP [38]. van der Meij et al. [38] reported
that by applying strict clinical and histological diagnostic modi-
ﬁed WHO  criteria, they were able to identify a subgroup of OLL
patients with high malignant potential. Recently, most follow-up
studies have applied strict clinical and histological diagnostic cri-
teria, and some of these have suggested malignant potential of OLP
[28–35,39,41–45]. A rigorously conducted 4.5-year follow-up study
of 723 cases found malignant transformation of 6 (0.8%) cases [30].
A Northern Italian cohort study of 402 OLP cases, which had been
selected based on strict clinical and histological diagnostic criteria,
showed that 9 cases developed an OSCC during a 4.9 year follow-up
[32]. A study of 145 patients deemed to have OLP, but not via strict
diagnostic criteria, reported malignant transformation in 4 cases, of
which 3 had dysplasia at the initial diagnosis [36]. Based on recent
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eports (Table 4), the overall malignant transformation rate of OLP
s estimated to be 1–2%, and higher rates of transformation in Italian
eports may  be due to a high prevalence of HCV infection [39,42].
The  preferential sites of OSCC which develops from OLP lesions
re the tongue and buccal mucosa, and the incidence is higher in
he former than the latter [11–42,87], while epithelial dysplasia in
LP is more prevalent in the buccal mucosa [86]. Interestingly, in
ome cases OSCC has reportedly arisen from the plaque form of
LP on the dorsum of the tongue [88], which is a rare location for
SCC, although most cases of OSCC associated with OLP are found
n the lateral side of the tongue [11–42], as is common of OSCC
1]. Smoking and alcohol use are evidently not risk factors for OSCC
evelopment in patients with OLP [89]. The red lesions, such as
rosive and atrophic forms of OLP, may  tend to progress to OSCC
4–6,11–46]. Erosive and atrophic forms of OLP are associated with
CV infection [39,42].
It  is uncertain what mechanisms could cause malignant trans-
ormation of OLP. A cytokine-based microenvironment arising from
hronic inﬂammation of OLP may  induce genetic alterations of
pithelial cells to progress to malignancy [90]. Such alterations
nclude increased loss of heterozygosity (LOH) at tumor suppres-
or gene loci, increased DNA content, and occurrence of aneuploidy
91–95]. Expression of apoptosis- and cell cycle-regulating proteins
uch as p53 protein, p21 protein, p16 protein, bcl-2, and bax is also
ltered in the transformation process [96–100]. These molecular
hanges may  be useful in further understanding malignant pro-
esses associated with OLP.
. Perspectives
Epithelial dysplasia is considered to be a risk factor for malig-
ant transformation into OSCC. A conception that OLP and lichenoid
ysplasia should be considered to be different entities is evidently
idely accepted [4,9,38]. Nevertheless, it would be also likely that
lichenoid dysplasia” (dysplasia observed in OLLs or OLP) is an
arly stage of malignant transformation pathway from “true” OLP
o OSCC, if “true” OLP is able to transform into dysplasia. A series
f clinical observations by Mignogna et al. [28,101,102] suggests
he latter viewpoint that “true” OLP may  have a malignant poten-
ial. They performed an extensive retrospective study of a cohort
f 45 patients with OLP who subsequently underwent the changes
o severe dysplasia and/or OSCC. Of 45 patients with histologically
iagnosed OLP without dysplasia at the time of the initial diagnosis,
0 patients subsequently had a single transformation event, and 25
ad multiple transformation events including multifocal dysplasia
nd/or malignancy. Their results suggest that not only is OLP itself
 risk factor for malignant transformation, but that there may  also
e ﬁeld cancerization in OLP [102].
Although the incidence of malignant transformation of OLP
emains controversial, careful, regular, and long-term follow-up
f patients with OLP is required for the early detection of malig-
ant transformation from OLP. The follow-up interval ranges from
 months to annually. Patients with the reticular form of OLP may
e assessed annually, while OLP with dysplasia should be examined
ore frequently, e.g. every 2–3 months [28,102]. If erosive changes
re evident in lesions at follow-up visits, additional biopsies are
andatory and the follow-up intervals should be shortened.
A  prospective, long-term, follow-up study with strict diagnostic
riteria will be required to clarify the malignant potential of OLP.eferences
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